Direxion Daily S&P Biotech Bear 3X ETF
LABD
11 hedge funds and large institutions have $28.7M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 3 closing their positions.
501% more call options, than puts
Call options by funds: $64.2M | Put options by funds: $10.7M
33% more capital invested
Capital invested by funds: $21.5M → $28.7M (+$7.18M)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
4.12% less ownership
Funds ownership: 17.49% → 13.37% (-4.1%)
86% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$1.11M |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$910K |
| 3 |
MMA
Miracle Mile Advisors
Los Angeles,
California
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$3.51M |
| 2 |
Morgan Stanley
New York
|
-$2.15M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.4M |
| 4 |
HF
HRT Financial
New York
|
-$1.26M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$638K |
LABD Hedge Fund Activity: Q4 2018 in Review
11 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q4 2018, worth a combined $28.7M — up 33% from $21.5M a quarter earlier.
Fund positioning in LABD was balanced in Q4 2018: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 7 trimmed.
The largest buyer was Traynor Capital Management, opening a new position worth an estimated $1.11M. The largest seller was Virtu Financial, cutting an estimated $3.51M.
- 11 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $28.7M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q4 2018, up 33% quarter-over-quarter.
- 3 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q4 2018 and 3 closed out, a net change of 0 holders.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q4 2018 was Traynor Capital Management, an estimated $1.11M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q4 2018 was Virtu Financial, an estimated $3.51M sold.
Based on aggregated 13F filings for Q4 2018.